Loading
A phase 3 trial of Margetuximab and Trastuzumab in Breast cancer, run by MacroGenics, completed.
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer is a phase 3 interventional study registered as NCT02492711 by MacroGenics, with 624 participants recorded, started 2015-08-24 and reaching its primary completion in 2021-08-11. Interventions recorded: Margetuximab, Trastuzumab, Physician's choice of chemotherapy.. Conditions recorded: HER-2 Positive Breast Cancer, Metastatic Neoplasm.
Linked to the drug Margetuximab because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
624 enrolled.
95% CI 5.52 to 6.97; Figures from the ClinicalTrials.gov results section (first posted 2022-11-23), not from a publication · 95% CI 4.17 to 5.59
Source95% CI 0.66 to 61.44; Figures from the ClinicalTrials.gov results section (first posted 2022-11-23), not from a publication · 95% CI 0.07 to 64.53
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) as Determined by Independent Radiological Review.primary | Margetuximab Plus Chemotherapy | 266 | 5.8 months | 0.76 (0.593 to 0.979) | 0.0334 | link |
| Trastuzumab Plus Chemotherapy | 270 | 4.9 months | ||||
| Overall Survival (OS) Defined as the Number of Days From Randomization to the Date of Death (From Any Cause).primary | Margetuximab Plus Chemotherapy | 266 | 21.6 months | 0.95 (0.774 to 1.165) | 0.6204 | link |
| Trastuzumab Plus Chemotherapy | 270 | 21.9 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MacroGenics, Margetuximab, Trastuzumab and the tag pipeline.
Shares Margetuximab, Trastuzumab, Breast cancer (all types) and the tag pipeline.
Shares Trastuzumab, Breast cancer (all types) and the tag pipeline.
Shares Trastuzumab, Breast cancer (all types) and the tag pipeline.
Shares MacroGenics and the tag pipeline.
Shares Trastuzumab, Breast cancer (all types) and the tag pipeline.
Shares Trastuzumab, Breast cancer (all types) and the tag pipeline.
Shares Trastuzumab, Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/